Poster endorsement? It was peer review medical publication. A CR on such low dosage so early in Ph1 is very rare where even @Mason14 said was excellent result and tried to discredit it by saying IMU then increase the dosage as management weren't seeing enough efficacy despite stating he is a "scientist" who is supposedly meant to know how Ph1 clinical trial are conducted for OBD.
IMU is the pick because of the potential in the next 8-12 months, I'm not sure what you mean by "murky combo treatment", a lot of new cancer treatment on clinical trial are in combination with approved cancer drug to find a better effective cancer treatment.
Poster endorsement? It was peer review medical publication. A CR...
-
- There are more pages in this discussion • 1,043 more messages in this thread...
You’re viewing a single post only. To view the entire thread just sign in or Join Now (FREE)
Add IMU (ASX) to my watchlist
 (20min delay)
|
|||||
|
Last
5.9¢ |
Change
0.005(9.26%) |
Mkt cap ! $433.6M | |||
| Open | High | Low | Value | Volume |
| 5.5¢ | 5.9¢ | 5.4¢ | $1.489M | 25.99M |
Buyers (Bids)
| No. | Vol. | Price($) |
|---|---|---|
| 2 | 35252 | 5.9¢ |
Sellers (Offers)
| Price($) | Vol. | No. |
|---|---|---|
| 6.0¢ | 1753430 | 24 |
View Market Depth
| Last trade - 16.10pm 12/07/2024 (20 minute delay) ? |
| IMU (ASX) Chart |